Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM
8.58
0.01 (0.12%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :21,575
Date :07-20-2017
* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs

July 18th, 2017|

JERUSALEM, July 18, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Simon Bruce MD to the newly created position of Vice […]

Oramed to Present at BIT’S 5th World Congress of Diabetes on July 13, 2017

July 12th, 2017|

JERUSALEM, July 12, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Miriam Kidron, Oramed’s Chief Scientific Officer, […]

Oramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program

July 11th, 2017|

JERUSALEM, July 11, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Food and Drug Administration (FDA) […]

Oramed Announces Dual-Listing on Tel Aviv Stock Exchange

July 5th, 2017|

JERUSALEM, July 5, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received approval from the Israel […]